Long-Term Efficacy of Lutonix in a Real-World Femoropopliteal Patients With Peripheral Arterial Disease: Insights From the SAFE-DCB US Registry - Takeaways - MDSpire

Long-Term Efficacy of Lutonix in a Real-World Femoropopliteal Patients With Peripheral Arterial Disease: Insights From the SAFE-DCB US Registry

  • By

  • Nicolas W. Shammas

  • Dion Franga

  • Erin Moore

  • George Mueller

  • Thomas P. Davis

  • Edward Woo

  • Investigators of SAFE-DCB US Registry

  • June 29, 2026

  • 0 min

Share

  • 1

    The Lutonix SAFE-DCB US Registry is the largest prospective multicenter study evaluating the Lutonix DCB in real-world patients.

  • 2

    The study included patients with stenotic or obstructive lesions in the superficial femoral artery and/or popliteal artery.

  • 3

    Primary effectiveness was measured by freedom from target lesion revascularization at 12 months post-procedure.

  • 4

    Primary safety endpoints included perioperative death, major amputation, and target vessel revascularization within 30 days.

  • 5

    The study aimed to address the evidence gap between randomized controlled trial data and long-term clinical performance.

Original Source(s)

Long-Term Efficacy of Lutonix in a Real-World Femoropopliteal Patients With Peripheral Arterial Disease: Insights From the SAFE-DCB US Registry

  • by Nicolas W. Shammas, Dion Franga, Erin Moore, George Mueller, Thomas P. Davis, Edward Woo, Investigators of SAFE-DCB US Registry

  • June 29, 2026

Related Content

In-Stent Stenosis or Occlusion After Carotid Artery Stenting in Patients Treated With Anticoagulants vs Antiplatelet Therapy

Distinct trajectories of low anterior resection syndrome following ileostomy reversal

Large language models for breast cancer treatment planning: a blinded real-world evaluation of DeepSeek, ChatGPT, and oncologist recommendations